Adamis Pharmaceuticals (ADMP) Given Daily Coverage Optimism Score of 0.02
Press coverage about Adamis Pharmaceuticals (NASDAQ:ADMP) has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.1629477921433 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Analysts Expect Adamis Pharmaceuticals Corp (ADMP) Will Announce Quarterly Sales of $4.05 Million (americanbankingnews.com)
- Zacks: Brokerages Anticipate Adamis Pharmaceuticals Corp (ADMP) to Announce -$0.15 EPS (americanbankingnews.com)
- Lookout Technical Indicators on Adamis Pharmaceuticals Corporation (ADMP) – Wall Street Morning (wallstreetmorning.com)
- Adamis Pharmaceuticals Corporation, (NASDAQ: ADMP) – Investor’s Alert (Technicals Data Analysis) – Stock Watch (stocksnewstimes.com)
- KMPH Gets FDA Nod, ADMP On Track, OBSV To Report Data Today – Markets Insider (markets.businessinsider.com)
ADMP has been the subject of a number of research reports. ValuEngine downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 30th. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Maxim Group set a $5.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Raymond James Financial set a $7.00 target price on Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 23rd. Finally, B. Riley set a $10.00 target price on Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Adamis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $7.33.
COPYRIGHT VIOLATION NOTICE: “Adamis Pharmaceuticals (ADMP) Given Daily Coverage Optimism Score of 0.02” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/04/adamis-pharmaceuticals-admp-given-daily-coverage-optimism-score-of-0-02.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.